Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon patch 10 cm2 vs 15 cm2 in Alzheimer's disease after decline on open-label treatment
2007-000213-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Novartis. Primary endpoint: Change from double-blind randomization baseline to Week 48 in ADAS-Cog total score. Started Jun 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-000213-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000213-11.